Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens implant study tracks eye pressure spikes

NCT ID NCT05538754

Disease control Sponsor: Staar Surgical Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how often eye pressure rises after getting an EVO ICL lens implant to correct nearsightedness and astigmatism. Researchers measured pressure in 205 people right after surgery. The goal was to see how many eyes had high pressure, which can be a risk after this type of implant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EVO ICL implantable lens
What this could lead to
If successful, this study could help doctors better manage eye pressure risks after lens implant surgery.
What could go wrong
This is a small, completed safety study, not a test of vision improvement. Results may not apply to all patients or lens types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

205 people

The number who actually took part.

Started

Sep 2022

Finished

Oct 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Moderate to high myopia correctable with available EVO ICL powers. * Moderate to high myopic with astigmatism correctable with available EVO ICL powers. * Stable refractive history within 0.50 D cylinder for 1 year prior to implantation. * Stable refractive history within 0.50 D for spherical equivalent 1 year prior to implantation. * Able and willing to return for scheduled follow-up examinations after surgery. * Able to read, understand and provide written informed consent on the Institutional Review Board (IRB) approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations. * Other protocol-specified inclusion criteria may apply. Exclusion Criteria: * Ocular hypertension or glaucoma. * Insulin dependent diabetes or diabetic retinopathy. * History of previous ocular surgery. * Monocular. * Pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study or has another condition with associated fluctuation of hormones that could lead to refractive changes. * Other protocol-specified exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astigmatism myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia Myopic astigmatism

Contacts and locations

Locations

  • Aloha Laser Vision, LLC

    Honolulu, Hawaii, 96814, United States

  • Cleveland Eye Clinic

    Brecksville, Ohio, 44141, United States

  • Durrie Vision

    Overland Park, Kansas, 66210, United States

  • Key-Whitman Eye Center

    Dallas, Texas, 75243, United States

  • Kugler Vision, PC

    Omaha, Nebraska, 68118, United States

  • Parkhurst NuVision

    San Antonio, Texas, 78229, United States

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

  • Vance Thompson Vision

    Sioux Falls, South Dakota, 57108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.